Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Go back to Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients| ARISTOTLE (NASDAQ: ARTL) | Delayed: 1.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.26 | 52 Week High | $6.22 | |||
| Open | $1.26 | 52 Week Low | $2.74 | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.26 | EPS | $-0.21 | |||
| Volume | 4,737 | |||||
